AURA Aura Biosciences, Inc.
Price Chart
Executive Summary
Aura Biosciences filed a preliminary prospectus supplement for an underwritten public offering of common stock and pre-funded warrants. The offering size is unspecified but will cause immediate and substantial dilution; proceeds will fund clinical programs and potentially repurchase up to 6,922,870 shares from Matrix Capital if net proceeds exceed $200M. The filing also discloses a CEO transition and that the Phase 3 CoMpass trial is nearing enrollment completion (86 patients as of May 4, 2026).
Actionable Insight
Monitor final pricing and size of the offering upon effectiveness; the stock will likely face downward pressure from dilution. Watch for execution of the stock repurchase, which could partially offset dilution but is contingent on offering proceeds exceeding $200M. The CEO transition adds management uncertainty, though the CoMpass trial update is neutral to slightly positive for the pipeline timeline.
Key Facts
- Offering of common stock and pre-funded warrants; all terms (size, price) are placeholders pending final pricing.
- Last reported sale price on May 1, 2026 was $7.01 per share; market cap ~$450M.
- Historical net tangible book value of $121.1M ($1.90/share) as of Dec 31, 2025; offering will cause immediate dilution.
- Preliminary cash, cash equivalents, and marketable securities of ~$114.7M as of March 31, 2026.
- Planned stock repurchase of up to 6,922,870 shares (10.8% of outstanding) from Matrix Capital, contingent on net proceeds exceeding $200M.
- CEO transition: Natalie Holles appointed effective April 30, 2026, succeeding founder Elisabet de los Pinos.
- Phase 3 CoMpass trial for bel-sar (early choroidal melanoma) nearing enrollment completion; topline data expected H2 2027.
Financial Impact
Significant dilution from offering; potential repurchase of ~10.8% of outstanding shares if net proceeds >$200M; no revenue or earnings disclosed.
Risk Factors
- Immediate and substantial dilution to existing shareholders.
- Stock repurchase may not occur if net proceeds are ≤$200M, leading to higher share count.
- Clinical-stage biotech with no approved products; reliance on bel-sar Phase 3 data.
- CEO transition introduces execution risk.
- No established public market for pre-funded warrants.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-202458 |
| Document: 0001193125-26-202458-index-headers.html | 0001193125-26-202458 |
| Document: 0001193125-26-202458-index.html | 0001193125-26-202458 |
| Document: 0001193125-26-202458.txt | 0001193125-26-202458 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 19, 2026
26d ago
|
Press Release
| $7.47 $7.50 | ▲ +0.40% | ▼ −1.40% | $6.41 (−14.19%) |
|
May 5, 2026
5w ago
|
8-K
| $8.29 $7.93 | ▲ +4.34% | ▲ +5.47% | $6.41 (+22.68%) |
|
May 5, 2026
5w ago
|
Press Release
| $8.29 $7.93 | ▲ +4.34% | ▲ +5.47% | $6.41 (+22.68%) |
|
May 4, 2026
5w ago
|
8-K
| $8.90 $7.93 | ▼ −10.90% | ▼ −12.88% | $6.41 (−27.98%) |
|
May 4, 2026
5w ago
|
Press Release
| $8.35 $8.19 | ▲ +1.92% | ▲ +4.85% | $6.41 (+23.23%) |
|
May 4, 2026
5w ago
|
424B5
| $8.35 $8.19 | ▲ +1.92% | ▲ +4.85% | $6.41 (+23.23%) |
|
May 4, 2026
5w ago
|
8-K
| $8.35 $8.19 | ▼ −1.92% | ▼ −4.85% | $6.41 (−23.23%) |
|
May 4, 2026
5w ago
|
Press Release
| $8.35 $8.19 | ▲ +1.92% | ▲ +4.85% | $6.41 (+23.23%) |
|
May 4, 2026
5w ago
|
Press Release
| $8.35 $8.19 | ▼ −1.92% | ▼ −4.85% | $6.41 (−23.23%) |
|
Apr 20, 2026
7w ago
|
DEFA14A
| $7.44 $6.96 | ▼ −6.45% | ▼ −7.54% | $6.41 (−13.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access